|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||78.00 - 81.18|
|52-week range||78.00 - 81.18|
|Beta (5Y monthly)||2.10|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.
Shares of Editas Medicine (NASDAQ: EDIT) were tumbling 16.3% as of 11:28 a.m. EST on Monday. The update that likely most rattled investors was that Editas' chief scientific officer, Charles Albright, is leaving the company to pursue another opportunity.